Despite the lack of an established set of measures to evaluate quality of care in medical oncology, Peter Salgo, MD; John L. Fox, MD, MHA; Michael Kolodziej, MD; and Bryan Loy, MD, note that initiatives that emphasize collaboration among stakeholders and ask healthcare providers to measure and report data from their clinical practices can be valuable in helping improve overall quality of patient care.
The American Society of Clinical Oncology’s Quality Oncology Practice Initiative and the ABIM Foundation’s Choosing Wisely initiative have already proved beneficial, especially in terms of improving end-of-life care, remarks Dr Kolodziej.
The concept of asking providers to measure their own data and report on their own findings can be valuable, adds Dr Loy. This information can be used along with a collaborative approach to address gaps in patient care.
Dr Fox discusses important strategies for implementing quality improvement programs, and notes that first and foremost, there must be consensus among stakeholders on how to define quality. Additionally, payers need to agree to reimburse for a single standard of quality. Identifying issues that matter and that can be measured is critical. Finding a way to pay for quality care is an additional challenge, comments Dr Fox.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More